Table 1.
Ferroptosis activators
| Classification | Compound/drug | Target/function |
|---|---|---|
| Activators | Cisplatin (CDDP) | Destroy DNA |
| Erastin | VDAC2/VDAC3 | |
| Gallic acid hydrate | COX-2 | |
| RSL3 ((1S,3R)-RSL3) | GPX4 | |
| TBHQ | Nrf2 | |
| Hemin | HO-1 | |
| Simvastatin (MK 733) | HMG-CoA reductase | |
| Pifithrin-α hydrobromide | P53 | |
| Lovastatin | HMG-CoA reductase | |
| PRIMA-1Met | P53; TrxR1 | |
| BAY 11–7085 (BAY 11–7083) | NF-κB; IκBα | |
| Atorvastatin hemicalcium salt (CI-981) | HMG-CoA reductase | |
| Sulfasalazine (NSC 667,219) | NF-κB | |
| Artesunate | STAT-3;EX1 (EXP1) | |
| L-Buthionine-(S,R)-sulfoximine | G-glutamylcysteine synthetase | |
| ML-210 | GPX4 | |
| iFSP1 | FSP1 (AIFM2) | |
| Piperlongumine | ERK1/2 signaling pathway | |
| Artemisinin (Qinghaosu) | Akt signaling pathway | |
| Brusatol (NSC 172,924) | Nrf2 | |
| Fluvastatin sodium | HMG-CoA reductase | |
| Withaferin A | NF-Kb; vimentin; EPCR | |
| Pravastatin sodium (CS-514 sodium) | HMG-CoA reductase | |
| DL-Buthionine-(S,R)-sulfoximine | Glutamylcysteine synthetase | |
| Matrine (Matridin-15-one) | Kappa opioid agonist | |
| Gallic acid | COX-2 | |
| L-Glutamic acid monosodium salt | Glutamate receptor | |
| (−)-Epicatechin | COX-1; iNOS | |
| Siramesine hydrochloride | The sigma-2 receptor agonist | |
| (S)-Glutamic acid | Glutamate receptors | |
| PD146176 (NSC168807) | 15-LO | |
| PRIMA-1 (NSC-281668) | TP53 | |
| L-Cystine | Cellular regulation | |
| Pseudolaric Acid B | T lymphocytes | |
| DL-Buthionine-(S,R)-sulfoximine hydrochloride | Glutamylcysteine synthetase | |
| Trigonelline | Nrf2 | |
| Chrysosplenetin | MDR1 and p-gp | |
| (E)-Ferulic acid | Remove ROS and inhibit lipid peroxidation | |
| Arteannuin B | Anti-SARS-CoV-2 | |
| Cerivastatin sodium | HMG-CoA reductase | |
| Siramesine(Lu 28–179) | Sigma-2 receptor agonist | |
| Cerivastatin | HMG-CoA reductase | |
| Dihydroartemisinic acid (Dihydroqinghao acid) | A natural product isolated from Artemisia annua |